Market research
NSB.AU NeuroScientific Biopharmaceuticals Limited
AU AUD Healthcare
Latest close
As of 27 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 0.43
- Dividend yield
- Not available
- Beta
- 1.23
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000012973
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 0.43
- Dividend yield
- Not available
- Beta
- 1.23
About
About NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
Research context
NeuroScientific Biopharmaceuticals Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NSB.AU discussion.
5 years, 6 months ago
NeuroScientific Biopharmaceuticals Limited is currently in a long term uptrend where the price is trading 25.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
NeuroScientific Biopharmaceuticals Limited's total revenue rose by 1408.2% to $444K since the same quarter in the previous year.
Its net income has increased by 35.2% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 37.3% to $-436K since the same quarter in the previous year.
Based on the above factors, NeuroScientific Biopharmaceuticals Limited gets an overall score of 5/5.